Research Topics
Species | Geoffrey R OxnardSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Screening for germline EGFR T790M mutations through lung cancer genotypingGeoffrey R Oxnard
Thoracic Oncology Service and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Thorac Oncol 7:1049-52. 2012..We hypothesized that patients with lung cancers found to harbor the EGFR T790M resistance mutation before treatment, an uncommon occurrence, would be likely to carry underlying germline T790M mutations...- Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinibGeoffrey R Oxnard
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
Clin Cancer Res 17:6322-8. 2011..To better understand these results, we studied the natural history of lung cancers which recurred despite adjuvant TKI... - Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutationGeoffrey R Oxnard
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York 10065, USA
Clin Cancer Res 17:1616-22. 2011..In half of these cases, a second EGFR mutation, T790M, underlies acquired resistance. We undertook this study to examine the clinical course of patients harboring the T790M mutation following progression on TKI... - EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinomaMai He
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Clin Cancer Res 18:1790-7. 2012..EGFR exon 19 insertions are a poorly described family of EGFR mutations, and their association with EGFR-TKI sensitivity in lung adenocarcinoma is uncertain... 
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial designJamie E Chaft
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
Clin Cancer Res 17:6298-303. 2011..To examine this observation and define the course of patients following TKI discontinuation, we systematically evaluated patients enrolled on clinical trials of agents to treat acquired resistance to erlotinib or gefitinib...- "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancerChristian Grommes
Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Neuro Oncol 13:1364-9. 2011..Pulsatile erlotinib can control CNS metastases from EGFR mutant lung cancer after failure of standard daily dosing. CNS disease may not harbor acquired resistance mutations that develop systemically. A prospective trial is planned... - Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutesGeoffrey R Oxnard
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
J Clin Oncol 29:3114-9. 2011..In this study, we assess the variability of lung tumor measurement using repeat CT scans performed within 15 minutes of each other and discuss the implications of this variability in a clinical context... - A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker developmentBinsheng Zhao
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 16:4647-53. 2010.... - Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutationsNatasha Rekhtman
Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
Clin Cancer Res 18:1167-76. 2012.... - Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assayMaria E Arcila
Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 17:1169-80. 2011..Using high sensitivity methods, the T790M is detected in up to 68% of these patients... 
Use of erlotinib or gefitinib as initial therapy in advanced NSCLCGeoffrey R Oxnard
Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Oncology (Williston Park) 24:392-9. 2010..Currently active trials are referenced using their ClinicalTrials.gov identifier...- Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modelingJuliann Chmielecki
Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA
Sci Transl Med 3:90ra59. 2011..This modeling predicted alternative therapeutic strategies that could prolong the clinical benefit of TKIs against EGFR-mutant NSCLCs by delaying the development of resistance... - Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancerGeoffrey R Oxnard
Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, 02215, USA
Arch Pathol Lab Med 136:1205-9. 2012.... - Non-small cell lung cancer in octogenarians: treatment practices and preferencesGeoffrey R Oxnard
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
J Thorac Oncol 2:1029-35. 2007..Treatment practices in this patient population are poorly described. In this report, we describe the treatment of a population of very elderly patients with NSCLC at a large teaching hospital... - Modeling of mesothelioma growth demonstrates weaknesses of current response criteriaGeoffrey R Oxnard
Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, 02114, USA
Lung Cancer 52:141-8. 2006..Application of the RECIST response criteria to mesothelioma thickness measurements yields PR and PD classifications based on smaller volume changes than for spherical tumors...